aehr20160823_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

August 22, 2016

 


 

AEHR TEST SYSTEMS

(Exact name of registrant as specified in its charter)

 

California

 

000-22893

 

94-2424084

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

400 KATO TERRACE
FREMONT, CA 94539

(Address of principal executive offices, including zip code)

 

510-623-9400

(Registrant’s telephone number, including area code)

 

 N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

 
 

 

 

Item 1.01 Entry into a Material Definitive Agreement. 

 

On August 22, 2016, Aehr Test Systems (the “Company”) entered into an Amendment to the Aehr Test Systems Convertible Note Purchase and Credit Facility Agreement and 9.0% Notes (the “Amendment”) with QVT Fund LP and Quintessence Fund L.P. (the “Purchasers”) which amends the Convertible Note Purchase Agreement and Credit Facility Agreement dated as of April 10, 2015 with Purchasers and each of the 9.0% Convertible Secured Notes Due 2017 issued or issuable thereunder (the “Notes”).

 

Pursuant to the Amendment, the maturity date of the Notes was extended from April 10, 2017 to April 10, 2019, and the conversion price of the Notes was reduced from $2.65 per share to $2.30 per share.

 

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number

 

Description

              10.1

 

Amendment to the Aehr Test Systems Convertible Note Purchase and Credit Facility Agreement and 9.0% Notes

  

 
 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

AEHR TEST SYSTEMS

 

 

 

 

 

 

By:

 /s/ KENNETH B. SPINK

 

 

 

 

Kenneth B. Spink
Vice President of Finance and

Chief Financial Officer

 

Date:  August 24, 2016